MX2012012502A - Compuestos pirimidinil indol. - Google Patents

Compuestos pirimidinil indol.

Info

Publication number
MX2012012502A
MX2012012502A MX2012012502A MX2012012502A MX2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A MX 2012012502 A MX2012012502 A MX 2012012502A
Authority
MX
Mexico
Prior art keywords
compounds
pyrimidinile
indir
cancer
treatment
Prior art date
Application number
MX2012012502A
Other languages
English (en)
Inventor
Wei-Guo Su
Jinshui Li
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2012012502A publication Critical patent/MX2012012502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona los compuestos pirimidinil indol como inhibidores novedosos de cinasas para el tratamiento de cáncer y enfermedades inflamatorias.
MX2012012502A 2010-04-27 2010-04-27 Compuestos pirimidinil indol. MX2012012502A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/072225 WO2011134140A1 (en) 2010-04-27 2010-04-27 Pyrimidinyl indole compounds

Publications (1)

Publication Number Publication Date
MX2012012502A true MX2012012502A (es) 2013-01-18

Family

ID=44860753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012502A MX2012012502A (es) 2010-04-27 2010-04-27 Compuestos pirimidinil indol.

Country Status (16)

Country Link
US (1) US8501166B2 (es)
EP (1) EP2563774B1 (es)
JP (1) JP5634596B2 (es)
KR (1) KR20130069641A (es)
CN (1) CN102858764B (es)
AU (1) AU2010351938B2 (es)
BR (1) BR112012027542A2 (es)
CA (1) CA2797428A1 (es)
MX (1) MX2012012502A (es)
MY (1) MY159995A (es)
NZ (1) NZ603802A (es)
PH (1) PH12012502137A1 (es)
RU (1) RU2552999C2 (es)
SG (1) SG185056A1 (es)
TW (1) TWI410419B (es)
WO (1) WO2011134140A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
KR20050110612A (ko) * 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EP1747215A1 (en) * 2004-05-12 2007-01-31 Aventis Pharmaceuticals, Inc. Substantially pure 2-{¬2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl|-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
WO2006076318A1 (en) * 2005-01-12 2006-07-20 Aventis Pharmaceuticals Inc. Monopotassium salt of an ikb kinase inhibitor
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds

Also Published As

Publication number Publication date
JP2013525381A (ja) 2013-06-20
CN102858764A (zh) 2013-01-02
NZ603802A (en) 2014-05-30
MY159995A (en) 2017-02-15
US20130058892A1 (en) 2013-03-07
HK1179952A1 (en) 2013-10-11
CA2797428A1 (en) 2011-11-03
AU2010351938B2 (en) 2014-10-30
EP2563774B1 (en) 2014-03-12
KR20130069641A (ko) 2013-06-26
EP2563774A4 (en) 2013-07-10
US8501166B2 (en) 2013-08-06
CN102858764B (zh) 2014-08-20
TWI410419B (zh) 2013-10-01
PH12012502137A1 (en) 2013-02-04
SG185056A1 (en) 2012-12-28
RU2552999C2 (ru) 2015-06-10
RU2012149812A (ru) 2014-06-10
BR112012027542A2 (pt) 2019-09-24
JP5634596B2 (ja) 2014-12-03
EP2563774A1 (en) 2013-03-06
TW201141851A (en) 2011-12-01
AU2010351938A1 (en) 2012-12-20
WO2011134140A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
CO7030960A2 (es) Inhibidores de pak para el tratamiento de los trastornos de proliferación celular
CR20150571A (es) Compuestos y composiciones terapéuticos
MX2012012527A (es) Compuestos quimicos.
GT201400133A (es) Inhibidores de bromodominios
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
MX389288B (es) Compuestos heterocíclicos útiles como inhibidores de proteína cinasa-1 dependiente de 3-fosfoinositido (pdk1).
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20130045A (es) Compuestos terapéuticos
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
UA112795C2 (uk) Біциклічні піразинонові похідні
CO6640285A2 (es) 5-alquinil-pirimidinas
IL282112A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
BR112018005851A2 (pt) derivados de pirrolo[2,3-d]pirimidina como inibidores de dyrk1 / clk1 duais
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CR20140528A (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1
WO2014113407A3 (en) Use of small molecule inhibitors targeting eya tyrosine phosphatase
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors

Legal Events

Date Code Title Description
FG Grant or registration